NewsBenzinga10x Genomics Raises FY2026 Sales Guidance from $610.000M-$630.000M to $625.000M-$635.000M vs $619.854M Est 10x Genomics Raises FY2026 Sales Guidance from $610.000M-$630.000M to $625.000M-$635.000M vs $619.854M Est Benzinga 2026.11.05 22:23 (GMT+0) Open on Benzinga Other news Swoosh and a Miss: Nike Investor Day Leaves Wall Street Cold-Footed Wall Street Says the AI Trade Is Over — ETF Investors Aren’t Acting Like It Citigroup Maintains Neutral on Westlake, Lowers Price Target to $65 Citigroup Maintains Neutral on LyondellBasell Industries, Lowers Price Target to $66 Caterpillar's 'Best-In-Class' Construction Business Is Getting Overlooked, Analyst Says How to Play NKE Stock as Nike Risks Becoming a Forever Turnaround Story